These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 24161322)

  • 1. Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease).
    Mentz RJ; Broderick S; Shaw LK; Fiuzat M; O'Connor CM
    J Am Coll Cardiol; 2014 Jan; 63(3):251-8. PubMed ID: 24161322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events.
    Mentz RJ; Broderick S; Shaw LK; Chiswell K; Fiuzat M; O'Connor CM
    Eur J Heart Fail; 2014 Aug; 16(8):854-60. PubMed ID: 24975128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Clinical characteristics and long-term outcomes of patients with ischemic cardiomyopathy with versus without angina pectoris (from the Duke Databank for Cardiovascular Disease).
    Mentz RJ; Fiuzat M; Shaw LK; Phillips HR; Borges-Neto S; Felker GM; O'Connor CM
    Am J Cardiol; 2012 May; 109(9):1272-7. PubMed ID: 22325975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center.
    Grubb AF; Pumill CA; Greene SJ; Wu A; Chiswell K; Mentz RJ
    Am Heart J; 2020 Dec; 230():25-34. PubMed ID: 32980363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease).
    Banks A; Broderick S; Chiswell K; Shaw L; Devore A; Fiuzat M; O'Connor C; Felker GM; Velazquez E; Mentz R
    Am J Cardiol; 2017 Jun; 119(11):1703-1709. PubMed ID: 28395884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
    Cunningham JW; Vaduganathan M; Claggett BL; John JE; Desai AS; Lewis EF; Zile MR; Carson P; Jhund PS; Kober L; Pitt B; Shah SJ; Swedberg K; Anand IS; Yusuf S; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2020 Aug; 8(8):618-626. PubMed ID: 32387067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of heart rate changes during hospitalization on outcome in heart failure with preserved ejection fraction.
    Liu D; Cui X; Xu Y; Xu L; Xie Z; Yuan S; Wang P; Wang Y; Qian S; Gong H; Nordbeck P; Yang J; Zhou J; Ge J; Sun A
    ESC Heart Fail; 2024 Oct; 11(5):2901-2912. PubMed ID: 38514992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of coronary artery disease in heart failure with preserved ejection fraction.
    Hwang SJ; Melenovsky V; Borlaug BA
    J Am Coll Cardiol; 2014 Jul; 63(25 Pt A):2817-27. PubMed ID: 24768876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Koh AS; Tay WT; Teng THK; Vedin O; Benson L; Dahlstrom U; Savarese G; Lam CSP; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1624-1634. PubMed ID: 28948683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China.
    Lyu S; Yu L; Tan H; Liu S; Liu X; Guo X; Zhu J
    BMC Cardiovasc Disord; 2019 Sep; 19(1):209. PubMed ID: 31477021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Badar AA; Perez-Moreno AC; Jhund PS; Wong CM; Hawkins NM; Cleland JG; van Veldhuisen DJ; Wikstrand J; Kjekshus J; Wedel H; Watkins S; Gardner RS; Petrie MC; McMurray JJ
    Eur Heart J; 2014 Dec; 35(48):3426-33. PubMed ID: 25265976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
    Badar AA; Perez-Moreno AC; Hawkins NM; Brunton AP; Jhund PS; Wong CM; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Gardner RS; Petrie MC; McMurray JJ
    Eur J Heart Fail; 2015 Feb; 17(2):196-204. PubMed ID: 25678097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
    Mentz RJ; Allen BD; Kwasny MJ; Konstam MA; Udelson JE; Ambrosy AP; Fought AJ; Vaduganathan M; O'Connor CM; Zannad F; Maggioni AP; Swedberg K; Bonow RO; Gheorghiade M
    Eur J Heart Fail; 2013 Jan; 15(1):61-8. PubMed ID: 22968743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
    Sandesara PB; Hammadah M; Samman-Tahhan A; Kelli HM; O'Neal WT
    Clin Cardiol; 2017 Sep; 40(9):692-696. PubMed ID: 28444995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verification of haemoglobin level to prevent worsening of prognosis in heart failure with preserved ejection fraction patients from the PURSUIT-HFpEF registry.
    Kitao T; Sotomi Y; Tamaki S; Seo M; Yano M; Hayashi T; Nakagawa A; Nakagawa Y; Nakatani D; Yamada T; Yasumura Y; Sakata Y;
    ESC Heart Fail; 2024 Oct; 11(5):3299-3311. PubMed ID: 38952180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Sartipy U; Dahlström U; Fu M; Lund LH
    JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
    Lund LH; Claggett B; Liu J; Lam CS; Jhund PS; Rosano GM; Swedberg K; Yusuf S; Granger CB; Pfeffer MA; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2018 Aug; 20(8):1230-1239. PubMed ID: 29431256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of angina pectoris and secondary events in patients with stable coronary heart disease (from the Heart and Soul Study).
    Beatty AL; Spertus JA; Whooley MA
    Am J Cardiol; 2014 Oct; 114(7):997-1002. PubMed ID: 25110069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction - A report from the JASPER registry.
    Sato Y; Yoshihisa A; Oikawa M; Nagai T; Yoshikawa T; Saito Y; Yamamoto K; Takeishi Y; Anzai T
    J Cardiol; 2019 Jun; 73(6):459-465. PubMed ID: 30718015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of coronary CT angiography in heart failure patients with preserved ejection fraction.
    Yu MM; Zuo WX; Zhao X; Tang XL; Chen YY; Dong LL; Shu XH; Jin H; Zeng MS
    Eur Radiol; 2023 May; 33(5):3052-3063. PubMed ID: 36629927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.